QX001S最初由荃信生物自主研发，2020年8月，公司与中美华东达成合作，由双方共同推进QX001S的III期临床试验，中美华东作为上市许可持有人负责中国大陆区域商业化，赛孚士负责产品生产及供应。QX001S是荃信生物研发管线中首个获批上市的产品，也是国内首个获批的乌司奴单抗注射液生物类似药。Quantum Pharmaceutical Group-B (02509) surged over 5%, as of the deadline, up 5.57%, at HK$11.38, with a turnover of 0.7366 million Hong Kong dollars.
According to the Wisdom Financial APP, Quantum Pharmaceutical Group-B (02509) surged over 5%, as of the deadline, up 5.57%, at HK$11.38, with a turnover of 0.7366 million Hong Kong dollars.
On the news front, on December 2, Huadong Medicine's wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhongmei Huadong") received the "Acceptance Notice" (Acceptance No.: CYSB2400311) issued by the National Medical Products Administration (NMPA), for the supplementary application of ustekinumab injection (R&D code: HDM3001/QX001S) for pediatric plaque psoriasis submitted by Zhongmei Huadong.
QX001S was initially independently developed by Quantum Pharmaceutical Group. In August 2020, the company collaborated with Zhongmei Huadong to jointly advance the Phase III clinical trial of QX001S. Zhongmei Huadong, as the marketing authorization holder, is responsible for commercialization in mainland China, while Cephalon is responsible for product manufacturing and supply. QX001S is the first product in Quantum Pharmaceutical Group's R&D pipeline to be approved for marketing, and it is also the first approved ustekinumab injection biosimilar in China.